Entries by Thomas Gabrielczyk

Trilogue put lights on green for Horizon Europe

The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliament’s proposal to increase its budget from €100bn to €120bn.

Genfit in $228m deal with Terns Pharmaceuticals

Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor  to Terns Pharmaceuticals Inc.
                                                                           

Researchers and bioethicists to pause germline editing

After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.

Karo Pharma acquires Trimb AB

Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).

UK biotech to make proteins from carbon dioxide emissions

Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.